Cenes Pharmaceuticals, Inc.
Records under this name other than patents Cenes Pharmaceuticals, Inc. holds now: patents now held by others, patents whose terms have ended, and its applications, pending or abandoned.
Back to Cenes Pharmaceuticals, Inc.
| Patent | Title | Status | Expires | Confidence |
|---|---|---|---|---|
| US 7,384,756 | Methods for treating muscle diseases and disorders Formerly held Term ended Term ended Jun 10, 2025 · From the USPTO record | Term ended | Term ended Jun 10, 2025 | From the USPTO record |
| US 7,285,531 | Method for prophylaxis or treatment of a nervous system, pathophysiological condition involving a glial growth factor sensitive cell by administration of a glial growth factor Formerly held Term ended Term ended Oct 23, 2024 · From the USPTO record | Term ended | Term ended Oct 23, 2024 | From the USPTO record |
| US 7,135,456 | Glial mitogenic factors, their preparation and use Formerly held Term ended Term ended Nov 14, 2023 · From the USPTO record | Term ended | Term ended Nov 14, 2023 | From the USPTO record |
| US 7,115,554 | Methods of increasing myotube formation or survival or muscle cell mitogenesis differentiation or survival using neuregulin GGF III Formerly held Term ended Term ended Oct 3, 2023 · From the USPTO record | Term ended | Term ended Oct 3, 2023 | From the USPTO record |
| US 7,037,888 | Methods for treating muscle diseases and disorders Formerly held Term ended Ended no later than May 2, 2023 · From the USPTO record | Term ended | Ended no later than May 2, 2023 | From the USPTO record |
| US 7,662,772 | Methods for treating congestive heart failure Formerly held Term ended Term ended Aug 3, 2021 · From the USPTO record | Term ended | Term ended Aug 3, 2021 | From the USPTO record |
| US 10,717,775 | Methods for Cardiomyocyte Survival,proliferation or Differentiation by NRG-2 Formerly held Term ended Term ended May 23, 2021 · High confidence | Term ended | Term ended May 23, 2021 | High confidence |
| US 10,232,016 | Methods for Treating Congestive Heart Failure Formerly held Term ended Ended no later than Nov 27, 2019 · Low confidence | Term ended | Ended no later than Nov 27, 2019 | Low confidence |
| US 6,444,642 | Methods of increasing myotube formation or survival or muscle cell mitogenesis, differentiation or survival using a neuregulin Formerly held Term ended Ended no later than Sep 3, 2019 · From the USPTO record | Term ended | Ended no later than Sep 3, 2019 | From the USPTO record |
| US 6,635,249 | Methods for treating congestive heart failure Formerly held Term ended Term ended Apr 23, 2019 · From the USPTO record | Term ended | Term ended Apr 23, 2019 | From the USPTO record |